Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will
present at the Stifel 2018 Healthcare Conference in New York, NY on
Tuesday, November 13th at 9:30 a.m. ET.
A live audio webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website. A replay will become
available approximately one hour after the event and will be archived
- Kevin Horgan, M.D. an accomplished drug developer and
immunology expert, hired as Chief Medical Officer -
- Planning for two new microbiome clinical studies in ulcerative
colitis and metastatic melanoma; Company expects to receive $40M in
payments from Nestlé Health Science with SER-287 Phase 2b study start -
- Conference call at 8:30 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2018--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on November 8, 2018
at 8:30 a.m. ET to discuss third quarter 2018 results and provide a
general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
9877087. To j...